Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Tumors formed by a highly metastatic human lung cancer cell line are characterized by activated signaling via vascular endothelial growth factor (VEGF)-C through its receptor (VEGFR-3) and aggressive lymph node metastasis. In this study, we examined how these highly metastatic cancers acquired aggressive lymph node metastasis. Compared with their lower metastatic counterparts, the highly metastatic tumors formed by this cell line expressed higher amounts of interleukin (IL)-1α, with similarly augmented expression of IL-1α and IL-1β by tumor stromal cells and of VEGF-A and VEGF-C by tumor-associated macrophages. These tumor-associated macrophages were mainly of the M2 type. Administration of a macrophage-targeting drug suppressed the production of these potent angiogenic and lymphangiogenic factors, resulting in decreased tumor growth, angiogenesis, lymphangiogenesis, and lymph node metastasis. In Matrigel plug assays, the highly metastatic cells formed tumors that were extensively infiltrated by M2-type macrophages and exhibited enhanced angiogenesis and lymphangiogenesis. All of these responses were suppressed by the IL-1 receptor (IL-1R) antagonist anakinra. Thus, the IL-1α-driven inflammatory activation of angiogenesis and lymphangiogenesis seems to provide a highly metastatic tumor microenvironment favorable for lymph node metastasis through cross-talk with macrophages. Accordingly, the IL-1R/M2-type macrophage axis may be a good therapeutic target for patients with this form of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022 · cited 1×
“Clinical studies have also demonstrated a close association between infiltration of tumor-associated macrophages (TAMs) and poor prognosis in patients with various human malignancies [16,17], suggesting that elevated inflammatory responses in the tumor microenvironment are important for malignant progression.”
BackgroundTrophic macrophages in development and disease
Pollard, J. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2528 · Cited by 1,178 · cited 2×
“Activated macrophages can be classified into inflammationstimulated M1 and M2 types [8,18].”
Background“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216
Cited by
Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Corliss, B. A., Azimi, M. S., Munson, J. M., Peirce, S. M., & Murfee, W. L. (2016) · Microcirculation · doi:10.1111/micc.12259 · Cited by 356
“Insulin-like growth factor 1 (IGF-1) Proangiogenic, prolymphangiogenic [28,266] IGF-2 Proangiogenic, prolymphangiogenic [28,265] IL-1a Proangiogenic, prolymphangiogenic [288,292] IL-1b Proangiogenic, prolymphangiogenic [288,292] IL-10 Antiangiogenic [299] IL-19 Proangiogenic [228] IL-20 Proangiogenic, antiangiogenic,…”
BackgroundRébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
IL-1 Family Members in Cancer; Two Sides to Every Story
Baker, K. J., Houston, A., & Brint, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01197 · Cited by 284
S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β
Weichand, B., Popp, R., Dziumbla, S., Mora, J., Strack, E., Elwakeel, E., Frank, A.-C., Scholich, K., Pierre, S., Syed, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160392 · Cited by 267
Zhang, X., Chen, Y., Hao, L., Hou, A., Chen, X., Li, Y., Wang, R., Luo, P., Ruan, Z., Ou, J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.004 · Cited by 99
Metadata
- Authors
- Watari, K., Shibata, T., Kawahara, A., Sata, K.-I., Nabeshima, H., Shinoda, A., Abe, H., Azuma, K., Murakami, Y., Izumi, H., Takahashi, T., Kage, M., Kuwano, M., & Ono, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-12
- Volume
- 9
- Issue
- 6
- Pages
- e99568
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2071896339
- Cited by
- 102
- References
- 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.